<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00863915</url>
  </required_header>
  <id_info>
    <org_study_id>20-679-1G</org_study_id>
    <nct_id>NCT00863915</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally as a Sprinkle on Applesauce</brief_title>
  <official_title>A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Ramipril10 mg Capsules Administered Orally as a Sprinkle on Applesauce</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the rate of absorption and oral bioavailability of a test formulation of&#xD;
      Ramipril10 mg Capsules manufactured by Purepac Pharmaceutical Company to an equivalent oral&#xD;
      dose of the commercially available reference product Atlace® manufactured by Monarch&#xD;
      Pharmaceuticals Inc. administrated as a sprinkle on one tablespoonful of applesauce to&#xD;
      healthy subjects after a 10-hour overnight fast&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: A single-dose, open-label, randomized, two-period&#xD;
      crossover study&#xD;
&#xD;
      Official Title: A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of&#xD;
      Ramipril10 mg Capsules Administered Orally as a Sprinkle on Applesauce&#xD;
&#xD;
      Further study details as provided by Actavis Elizabeth LLC:&#xD;
&#xD;
      Primary Outcome Measures:&#xD;
&#xD;
      Rate and Extend of Absorption&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramipril10 mg Capsules, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atlace® 10 mg capsules, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril10 mg Capsules, single dose</intervention_name>
    <description>A: Experimental Subjects received Purepac formulated products sprinkled on one tablespoonful of applesauce</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Ramipril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atlace® 10 mg capsules, single dose</intervention_name>
    <description>B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products sprinkled on one tablespoonful of applesauce</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Ramipril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be a male or non-pregnant, non-breast-feeding female.&#xD;
&#xD;
          -  Subject must be between 18 and 55 years of age inclusive.&#xD;
&#xD;
          -  Subject's body weight should be within ±15% of the ideal body weight for their height&#xD;
             and estimated frame based on the Metropolitan Life Insurance Company Table.&#xD;
&#xD;
          -  Female subjects of childbearing potential --- not surgically sterile or at least two&#xD;
             years postmenopausal-- must agree to utilize one of the following forms of&#xD;
             contraception, if sexually active with a male partner, from screening through&#xD;
             completion of the study. Approved forms of contraception are abstinence, hormonal&#xD;
             (oral, implant, transdermal or injection), double barrier (condom and diaphragm with&#xD;
             spermicide), IUD, or vasectomized partner (6 months minimum).&#xD;
&#xD;
          -  Subject must voluntarily consent to participate in this study and provide their&#xD;
             written informed consent prior to completion of any study-specific procedures.&#xD;
&#xD;
          -  Subject is willing and able to remain in the research center for the entire duration&#xD;
             of each confinement period and return to the research center for any outpatient&#xD;
             visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinically significant cardiovascular, pulmonary, hepatic,&#xD;
             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
             neurologic, oncologic or psychiatric disease or any other condition which, in the&#xD;
             opinion of the Investigator would jeopardize the safety of the subject or the validity&#xD;
             of the study results.&#xD;
&#xD;
          -  Has a clinically significant abnormal finding on the physical exam, medical history or&#xD;
             clinical laboratory results at screening.&#xD;
&#xD;
          -  History or presence of allergic or adverse response to the study drug or related&#xD;
             drugs.&#xD;
&#xD;
          -  Has been on a significantly abnormal diet during the four weeks preceding the first&#xD;
             dose of study medication.&#xD;
&#xD;
          -  Has donated blood or plasma within 30 days prior to the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Has participated in another clinical trial within 30 days prior to first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Has used any over-the-counter (OTC) medication including vitamins, within 7 days prior&#xD;
             to the first dose of study medication.&#xD;
&#xD;
          -  Has used any prescription medication, except hormonal contraceptive or hormonal&#xD;
             replacement therapy, within 7 days prior to the first dose of study medication.&#xD;
&#xD;
          -  Has been treated with any known enzyme altering drugs such as barbiturates,&#xD;
             phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the first&#xD;
             dose of study medication.&#xD;
&#xD;
          -  Has smoked or used tobacco products within 60 days prior to the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Has a history of substance abuse (including alcohol) in the past 5 years&#xD;
&#xD;
          -  Is female with a positive pregnancy test.&#xD;
&#xD;
          -  Positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines,&#xD;
             cocaine, cannabinoids, opiates).&#xD;
&#xD;
          -  Has had a positive test for, or has been treated for hepatitis B, hepatitis C or HIV.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel V. Freeland,, D.O., CCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEDRA Clinical Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CEDRA Clinical Research, LLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Meena Venugopal, Director, Clinical R&amp;D</name_title>
    <organization>Actavis Inc</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Ramipril</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

